论文部分内容阅读
为评价国产重组人类促红细胞生成素 (rhEPO)防治早产儿贫血的效果和安全性 ,将40例胎龄≤34周的早产儿随机分为治疗组及对照组各20例。治疗组予国产rhEPO750IU/(kg·w) ,每周分3次皮下注射 ,用药6周 ;对照组未用rhEPO ;两组早产儿均口服铁剂。结果显示治疗组用药后血清促红细胞生成素水平显著高于对照组 (P<0.01) ;治疗组血红蛋白、红细胞压积比、网织红细胞均显著高于对照组 (P<0.01) ;血清铁蛋白水平在用药后治疗组明显低于对照组 (P<0.01) ;治疗组输血率较对照组明显减少 (P<0.05) ;治疗组体重增长指标高于对照组 (P<0.05)。研究提示 ,国产rhEPO能有效防治早产儿贫血 ,且用药安全 ,无明显副作用
To evaluate the efficacy and safety of domestic recombinant human erythropoietin (rhEPO) in the prevention and treatment of anemia in premature infants, 40 preterm infants with gestational age ≤34 weeks were randomly divided into treatment group and control group with 20 cases each. The treatment group was given domestic rhEPO750IU / (kg · w), subcutaneous injection 3 times a week for 6 weeks; the control group did not use rhEPO; two groups of preterm children were oral iron. The results showed that the level of serum erythropoietin in the treatment group was significantly higher than that in the control group (P <0.01). The hemoglobin, hematocrit ratio and reticulocyte in the treatment group were significantly higher than those in the control group (P <0.01) (P <0.01). The blood transfusion rate of the treatment group was significantly lower than that of the control group (P <0.05). The body weight gain of the treatment group was higher than that of the control group (P <0.05). Research suggests that domestic rhEPO can effectively prevent anemia in preterm infants, and medication safety, no significant side effects